

Development of BCMA-targeting CAR-MILs for Treatment of Relapsed/Refractory Multiple Myeloma



ONCOLOGY	Preclinical
Product Type	Gene/Cell Therapy & Nucleic acids
Indication	Relapsed/Refractory Multiple Myeloma (R/R MM) patients who have failed ≥ 4 prior lines of therapy, including proteasome inhibitors, IMiDs, and anti-CD3
Target	B Cell Maturation Antigen (BCMA; CD269, TNFRSF13C)
MoA (Mechanism of Action)	Dual-epitope CAR-engineered MILs recognize and eliminate BCMA-positive MM cells via cytotoxicity and cytokine secretion. Memory T cell dominance ensures durable antitumor effect and relapse prevention.
Competitiveness	<ul style="list-style-type: none"> - Superior bone marrow homing and persistence compared to CAR-T - Strong cytotoxicity even against patient-derived MM cells - Low toxicity profile - Overcomes CAR-T resistance by polyclonal antigen recognition from MILs
Development Stage	Preclinical
Route of Administration	Intravenous (IV) – single infusion

Any unauthorized distribution or reproduction of this material is strictly prohibited.